Sustained-Release Injectable Products

Edited by
Judy H. Senior
and
Michael Radomsky

Interpharm Press
Denver, Colorado
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preface</td>
<td>xiii</td>
</tr>
<tr>
<td></td>
<td>Contributors</td>
<td>xvii</td>
</tr>
<tr>
<td>1.</td>
<td><strong>Rationale for Sustained-Release Injectable Products</strong></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td><em>Judy H. Senior</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rationale for Using Sustained Release for Systemic/Local</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Delivery of Drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Technologies: Spicing It Up</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>The Common Hurdles: Lessons from Complementary and</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Competing Technologies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>This Book</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>11</td>
</tr>
<tr>
<td>2.</td>
<td>**Product Development Principles of Sustained-Release</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Injectable Formulations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Michael Radomsky</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Product Development Strategy</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Product Development Timeline</td>
<td>16</td>
</tr>
</tbody>
</table>
3. Commercial Sustained-Release Injectable Formulations by Encapsulation

Mantripragada B. Sankaram

Drug Products, Drug Substances, and Excipients

Lipid-Based Drug Products
Polymer-Based Drug Products

Storage and Handling Requirements
Dosage and Administration
Products in Development
Conclusions
References

4. Insoluble Salt Forms and Drug Complexes

Judy H. Senior

General Physical and Pharmaceutical Characteristics of Insoluble Drug Complexes

Formulation Requirements
Considerations in Sterile Manufacture
Pharmacokinetics, Dosage, and Therapeutic Applications
Toxicity and Safety Considerations

A Survey of Commercial and Experimental Insoluble Drug Products

Formulation Characteristics
Comparative Pharmacokinetics, Typical Dosage, and Administration
Typical In Vivo Fate of Insoluble Drug Complexes
Experimental Approaches and Future Products

Advantages and Limitations of Insoluble Salts in Sustained Release

Future Trends
References
5. Non-aqueous Solutions and Suspensions as Sustained-Release Injectable Formulations 71
   Sudaxshina Murdan and Alexander T. Florence
   The Oil Vehicle 75
   Fate of the Oil Vehicle Following Administration
   Drug Absorption from Oil Solutions and Suspensions 83
   Factors Influencing Drug Absorption from Oil Solutions and Suspensions
   Adverse Effects of Sustained-Release Oil Solutions and Suspensions 99
   Conclusions 102
   References 102

6. Emulsions for Sustained Drug Delivery 109
   Maninder Hora and Stephen Tuck
   Historical Background 110
   Emulsions as Colloidal Drug Carriers 111
   Preparation and Properties 112
   Manufacturing Processes
   Characterization Techniques
   Stability
   Applications to Drug Delivery 122
   Carriers for Small Molecules
   Carriers for Biologics
   Outstanding Issues 130
   Characterization and Stability of Drug-Emulsion Formulations
   Mode of Action
   Conclusion 132
   Acknowledgments 132
   References 132

7. Liposomes for Local Sustained Drug Release 137
   Christien Oussoren, Gert Storm, Daan J. A. Crommelin, and Judy H. Senior
   Liposomes as Pharmaceutical Dosage Forms 138
   Typical Methods for the Preparation of Liposomes
   Stability of Liposome Formulations During Storage
10. In Situ Gelling Systems 241

Arthur J. Tipton and Richard L. Dunn

Overview and Rationale for In Situ Gelling Systems 241

Types of Systems 243

Lower Critical Solution Temperature
Liquid Crystalline
Polymer Precipitation
Sucrose Ester Precipitation
Biodegradable Acrylate-Terminated Polymers
Acrylate-Terminated PEG-PLA
Other Systems

Drug Candidates for In Situ Gelling Systems 265

Technology Limitations 267

Future Trends with In Situ Gelling Systems 268

References 270


Praveen Tyle, Ge Chen, and Leo Pavliv

Characteristics of an Ideal Vehicle 281

Undesirable Drug Characteristics for Sustained-Release Delivery 281

Decision Factors 282

Physicochemical Properties of Drugs
Biological Factors Influencing the Selection of Sustained-Release Systems
Delivery Issues

Formulation Considerations 285

Liposomes
Polymeric Delivery Systems

Case Studies 299

An Emulsion Formulation of Growth Hormone
AmBisome®
Lupron Depot®

Conclusion 304

References 305
12. Veterinary Sustained-Release Parenteral Products 309

Jung-Chung Lee and Michael Putnam

Sustained-Release Dosage Form Design Considerations 310

Absorption Parameters
Species Variations
Handling of Injection Equipment
Injection Sites

Basis for the Sustained-Release Dosage Form Design 320

Solutions
Suspensions
Liposomes
Implants

Current Marketed Veterinary Sustained-Release Parenteral Products 329

Conclusion 330
Acknowledgments 330
References 331

13. Applications in Vaccine and Gene Delivery 335

Maninder Hora and Ramachandran Radhakrishnan

Vaccines 336

Challenges in Vaccine Delivery
Requirements for Sustained-Action Vaccine Dosage Forms
Sustained-Action Technologies for Vaccine Delivery
Liposomes
Unmet Needs and Future Directions in Sustained Vaccine Delivery

Gene Delivery 348

Historical Perspectives
Desired Attributes of a Sustained-Release Gene Delivery System
Sustained-Action Systems for Gene Delivery
Future Directions in Gene Delivery

Acknowledgments 362
References 362

14. Microspheres for Protein and Peptide Delivery: Applications and Opportunities 371

Paul A. Burke and Scott D. Putney

Overview of Protein Encapsulation 379
Uses of Microspheres to Deliver Proteins 384
Systemic Delivery
Local Delivery
Delivery to Protected Sites
Vaccines

Conclusions 395
Acknowledgments 396
References 396

15. Toxicology and Biocompatibility Evaluation of Microsphere and Liposome Sustained-Release Drug Delivery Systems 409

M. Gary I. Riley and Scott D. Putney

Biocompatibility of Injectable, Sustained-Release Products 411
- Biocompatibility of Biodegradable Polymeric Delivery Devices
- Biocompatibility of Nondegradable Polymeric Delivery Devices
- Effect of Polymer Surface Features on Biocompatibility
- Biocompatibility of Liposomes
- The Design of Studies to Evaluate Biocompatibility

Toxicology of Injectable, Sustained-Release Products 416
- Drug Exposure
- Toxicity of Polymeric Delivery Devices
- Toxicity of Liposomal Delivery Devices
- Design of Studies to Evaluate Toxicity

Conclusions 421
References 422

16. Scale-Up, Validation, and Manufacturing of Microspheres 427

Kunio Kawamura

Scale-up and Technology Transfer 430
Manufacturing Methods 431
- Microsphere Fabrication Techniques
- Scale-Up
- Case Study: Lupron Depot®

Raw Material Procurement 437
In Vitro Drug Release Studies 437
- In Vitro Drug Release
- In Vivo Drug Release
- Correlation Between the In Vitro and In Vivo Drug Release Profile

Sterility Assurance 439
17. **Quality Control Methods and Specifications**

Johanna K. Lang

General Strategies for the Selection of Quality Control Methods

Product Characteristics of a Sustained-Release Injectable Formulation

Release Assays

Stability Assays

Method Development and Validation

Assays Covered Under the ICH Guidelines

Assays Not Covered Under the ICH Guidelines

Approaches to Setting Product Specifications

Manufacturing History

Fitness for Use

Analytical Method Limits

Compendial Limits

Regulatory Expectations and Changing Industry Standards

QC Assays, Validation, and Specifications in Real-Life Product Development

References

Appendix: Definitions of Validation Parameters from ICH Harmonized Tripartite Guideline: Text on Validation of Analytical Procedures, ICH Topic Q2A

18. **Regulatory Perspectives and Product Approval Processes**

Natalie L. McClure

General Principles of Drug Development

Case Study: Development of the Various Formulations of Leuprolide Acetate
Areas of Emphasis for Sustained-Release Drug Products 488
  Drug Release Profile Studies
  In Vitro/In Vivo Correlation Studies
  Excipient Characterizations

U.S. Regulatory Considerations 491
  Drug, Device, or Biologic Product?
  The New Drug Application

European Regulatory Considerations 493
  Centralized Application Process
  Mutual Recognition Application Procedure
  Combination Products

Conclusion 503

References 505

Index 507